Androgenetic Alopecia Explained: Causes, DHT, and Progression

Introduction: Why Androgenetic Alopecia Deserves a Deeper Look

Androgenetic alopecia (AGA) affects an estimated 1.0 to 1.5 billion individuals worldwide, making it one of the most prevalent dermatological conditions on the planet. Up to 80% of Caucasian men and nearly 50% of women will experience some degree of AGA by age 70. Despite these staggering numbers, most explanations of the condition stop at a surface level: “DHT causes hair loss.”

This article goes significantly deeper. Readers will gain a comprehensive understanding of the molecular cascade that drives follicle miniaturization, the complex genetics underlying susceptibility, the staging systems clinicians use to assess progression, the psychological burden many patients experience, the systemic health associations that make AGA more than a cosmetic concern, and the full spectrum of treatment options available in 2026.

Charles Medical Group, a practice with over 25 years of exclusive specialization in hair restoration, brings authoritative insight to this topic. Dr. Glenn Charles, the practice’s founder, has authored and edited the field’s most widely recognized textbooks on hair transplantation and serves as Past President of the American Board of Hair Restoration Surgery. The information presented here reflects a commitment to science-backed, honest, and patient-centered education.

What Is Androgenetic Alopecia?

Androgenetic alopecia is the most common form of non-scarring hair loss in adults, accounting for approximately 95% of all male hair loss cases. The condition is also known as male pattern hair loss (MPHL) or female pattern hair loss (FPHL) depending on the patient’s sex.

AGA should be distinguished from other forms of alopecia. Alopecia areata is an autoimmune condition causing patchy hair loss. Telogen effluvium involves diffuse shedding triggered by stress, illness, or hormonal shifts. Scarring alopecias destroy the follicle permanently through inflammatory processes. AGA, by contrast, is driven by two key factors: genetic predisposition and androgen sensitivity.

Understanding that AGA is a progressive, chronic condition rather than an acute event carries important implications for treatment strategy. Early intervention consistently produces better outcomes than waiting for advanced hair loss to develop.

The Genetics of AGA: Far More Complex Than “It Runs in the Family”

Twin and familial studies estimate AGA heritability at approximately 80%, making it one of the most heritable dermatological traits known. However, the genetics are far more complex than simple inheritance patterns suggest.

AGA exhibits a polygenic architecture, meaning it results from the cumulative effect of many genetic variants rather than a single gene. A landmark genome-wide association study (GWAS) in over 70,000 men identified 71 independent susceptibility loci explaining approximately 38% of SNP-heritability. These findings implicate multiple biological pathways, including the androgen receptor, WNT signaling (WNT10A, LGR4, RSPO2, DKK2), TGF-β, and apoptosis pathways.

The androgen receptor (AR) gene on the X chromosome represents the most strongly confirmed genetic locus for AGA. This finding explains why maternal inheritance is often cited, but it does not tell the whole story. Sons of balding fathers have a 5 to 6 times higher relative risk of developing AGA, confirming strong familial predisposition regardless of maternal line.

A critical research gap exists: polygenic risk scores trained on European cohorts perform poorly in African and other non-European populations, with AUC values of only 0.513 to 0.546 in African GWAS studies. This underscores the urgent need for ancestry-diverse genetic research.

Sex Differences in Genetic Risk: Male vs. Female AGA

Female AGA has a partially distinct genetic and hormonal profile from male AGA. It is not simply a milder version of the same condition. Declining estrogen levels during menopause can unmask underlying genetic predisposition in women, and there is a clinically relevant association between female AGA and polycystic ovary syndrome (PCOS).

The female AGA genetic architecture remains understudied relative to male AGA. This distinction matters for treatment, as therapies effective in men are not always appropriate or equally effective in women.

The Molecular Cascade: How DHT Actually Destroys Hair Follicles

Understanding the step-by-step biochemical sequence that drives follicle miniaturization provides essential context for treatment decisions. Dihydrotestosterone (DHT) is a potent androgen approximately 10 times more potent than testosterone, produced from testosterone via the enzyme 5-alpha reductase. Critically, this cascade only occurs in genetically susceptible follicles, which explains why donor hair from the back and sides of the scalp remains unaffected and can be used in transplantation.

Step 1: Genetic Susceptibility and Androgen Receptor Density

Individuals with AGA have an increased abundance of androgen receptors specifically in balding scalp regions (frontal and vertex zones). The AR gene variant associated with AGA encodes androgen receptors with heightened sensitivity to DHT. These receptors bind DHT more readily and trigger stronger downstream responses.

This receptor density difference explains why the same circulating DHT level causes hair loss in susceptible individuals but not in others. Genetic susceptibility is the prerequisite; without it, DHT alone does not cause AGA.

Step 2: 5-Alpha Reductase Type II Converts Testosterone to DHT

Two isoforms of 5-alpha reductase exist. Type I is found primarily in sebaceous glands and skin, while Type II is the dominant isoform in hair follicle dermal papilla cells and the most clinically relevant to AGA. Individuals with AGA show elevated 5-alpha reductase activity and elevated DHT production in scalp tissue.

This distinction matters clinically: finasteride selectively inhibits Type II, which is why it works specifically on scalp follicles. Dutasteride inhibits both Type I and Type II, producing broader DHT suppression.

Step 3: DHT Binds to Androgen Receptors in Dermal Papilla Cells

DHT enters the dermal papilla cell, binds to the androgen receptor, and the DHT-AR complex translocates to the nucleus. Once there, the complex acts as a transcription factor, altering gene expression in ways that harm follicle function. This binding event is the primary target of androgen receptor blockers like clascoterone (topical) and spironolactone (systemic in women).

Step 4: Suppression of the Wnt/β-Catenin Pathway

The Wnt/β-catenin pathway is a critical signaling cascade that promotes hair follicle development, stem cell activation, and the initiation and maintenance of the anagen (growth) phase. DHT-AR signaling suppresses Wnt/β-catenin activity in susceptible follicles, effectively silencing the molecular machinery that drives hair growth.

GWAS-identified genes in this pathway (WNT10A, LGR4, RSPO2, DKK2) have all been implicated in AGA susceptibility, confirming the pathway’s central role. Without adequate Wnt/β-catenin signaling, follicles cannot sustain normal anagen duration or follicle size.

Step 5: Upregulation of TGF-β Signaling

Transforming growth factor beta (TGF-β), when upregulated in dermal papilla cells, actively promotes follicle regression and inhibits proliferation. DHT-AR signaling increases TGF-β expression in susceptible follicles, creating a pro-miniaturization environment that shortens anagen, promotes catagen (regression phase) entry, and inhibits the proliferation of follicle keratinocytes.

Step 6: Follicle Miniaturization and Anagen Shortening

The end result of this molecular cascade is progressive follicle miniaturization: the gradual reduction in follicle size, hair shaft diameter, and hair pigmentation over successive hair cycles. In healthy follicles, anagen lasts 2 to 6 years. In AGA-affected follicles, it progressively shortens to months, then weeks, producing shorter, finer hairs with each cycle.

Thick, pigmented terminal hairs are gradually replaced by thin, unpigmented vellus hairs, and eventually the follicle may become dormant. Early intervention can halt or reverse miniaturization, but advanced miniaturization with follicle dormancy may be irreversible without surgical intervention.

How AGA Progresses: Staging Systems Explained

The stage of AGA at presentation directly determines the appropriate treatment strategy. Two primary classification systems exist: the Hamilton-Norwood Scale for men and the Ludwig Scale for women.

The Hamilton-Norwood Scale: Mapping Male Pattern Baldness

This scale describes progression from Stage I (minimal or no recession) through Stage VII (only a horseshoe-shaped band of hair remaining on the sides and back). The typical pattern begins with bitemporal recession and/or crown thinning, with the two zones eventually merging in advanced stages.

Stages I through III favor medical prevention. Stages IV and V benefit from combination medical and procedural approaches. Stages VI and VII typically require surgical planning. Not all men progress to advanced stages; the rate and extent of progression are influenced by genetic load, age of onset, and whether treatment is initiated.

The Ludwig Scale: Understanding Female Pattern Hair Loss

The Ludwig scale describes three grades: Grade I (mild thinning at the crown part line), Grade II (more pronounced widening and thinning), and Grade III (severe diffuse thinning with visible scalp). The key distinguishing feature of female AGA is diffuse crown thinning with preservation of the frontal hairline, in contrast to the recession pattern typical in men.

Who Is Affected: Prevalence, Demographics, and Ethnic Differences

Prevalence data for Caucasian men shows approximately 30% affected in their 30s, 40% in their 40s, 50% in their 50s, and rising to 80% by age 70. AGA affects nearly 50% of women by age 70, making it far more common in women than is widely recognized.

Ethnic differences exist: Caucasians are most affected, while Asians and African Americans show lower rates. In Korea, approximately 50% of men and 25% of women are affected by age 70. The global AGA treatment market was valued at approximately $3.0 billion in 2023 and is projected to reach $6.7 to 7.3 billion by 2033 to 2034.

The Psychological and Psychosocial Burden of Hair Loss

The emotional impact of AGA is a legitimate medical concern, not a vanity issue. A 2025 study found that 78% of women with alopecia experienced shame, anxiety, and depression, and 85% reported reduced self-esteem. Psychological distress, reduced self-confidence, and social anxiety are common across both sexes.

Effective treatment has been shown to improve quality of life metrics, reinforcing the value of early intervention.

AGA as a Health Marker: Comorbidities and Systemic Associations

AGA may signal broader systemic health risks. A meta-analysis of 19 studies (2,531 participants) found AGA patients have 3.46 times higher odds of metabolic syndrome, along with significantly worse BMI, waist circumference, fasting glucose, blood lipids, and blood pressure profiles.

Vertex-pattern AGA in men has been linked to early atherosclerosis, coronary heart disease, and prostate enlargement. Female AGA is associated with polycystic ovary syndrome. These are associations, not proven causal relationships, but they underscore the importance of comprehensive medical evaluation for patients presenting with AGA.

Treatment Options: From Medical Management to Surgical Restoration

The optimal approach depends on stage, sex, age, health status, and patient goals. Combination therapy is increasingly recognized as the 2026 gold standard. Real-world data shows oral minoxidil plus finasteride achieved stable or improved outcomes in 92.4% of 502 patients over 12 months.

FDA-Approved Medical Therapies

Topical minoxidil (approved 1988) works through vasodilation and potassium channel opening, prolonging anagen. Low-dose oral minoxidil has emerged as a major clinical advancement, with a 2025 international Delphi consensus statement addressing initiation protocols.

Oral finasteride (approved 1997) is a selective 5-alpha reductase Type II inhibitor, reducing scalp DHT by approximately 60 to 70%. The FDA issued warnings in October 2025 regarding mental health risks, though sexual dysfunction side effects occur in fewer than 2% of patients and are typically reversible.

Low-level laser therapy (LLLT) is an FDA-cleared device-based option available through products like LaserCap®. Spironolactone is used off-label in women, particularly those with hormonal contributors such as PCOS.

Emerging and Investigational Treatments

Clascoterone 5% topical solution reported breakthrough Phase 3 results in December 2025, showing up to 539% relative improvement in target-area hair count versus placebo. US and EU regulatory submissions are underway, potentially representing the first new therapeutic mechanism for AGA in over 30 years.

Other emerging options include platelet-rich plasma (PRP), exosome therapy, stem cell approaches, siRNA-based therapies, and AI-assisted personalized treatment planning. Charles Medical Group offers Alma TED™ as an advanced non-surgical technology for hair restoration support.

Surgical Hair Restoration: When and Why It Is Considered

Surgical restoration is typically considered when significant miniaturization has occurred and medical therapy alone cannot restore meaningful density. Follicular Unit Extraction (FUE) is the current gold standard: individual follicle extraction, minimally invasive, no linear scar, and faster recovery.

Charles Medical Group was among the first practices in the world to acquire the ARTAS Robotic Hair Restoration System and served as a Clinical Observation Center for training surgeons internationally. Scalp Micropigmentation (SMP) offers a non-surgical option for patients who are not surgical candidates.

Surgery does not stop the underlying AGA process. Ongoing medical management is typically recommended post-transplant to protect existing hair.

Lifestyle Factors That Can Accelerate AGA Progression

Lifestyle factors do not cause AGA in the absence of genetic predisposition, but they can significantly accelerate progression. Chronic stress, nutritional deficiencies (iron, vitamin D, protein), smoking, and obesity have all been documented as modulators of hair cycle health. Addressing modifiable lifestyle factors is a meaningful complement to medical treatment.

Conclusion: Understanding AGA Is the First Step Toward Effective Action

The molecular cascade from genetic susceptibility through DHT production, androgen receptor binding, Wnt/β-catenin suppression, TGF-β upregulation, follicle miniaturization, and anagen shortening represents the core biology of androgenetic alopecia. AGA is a progressive, chronic, and highly treatable condition. Early intervention consistently produces better outcomes.

Treatment is not one-size-fits-all. The optimal approach requires individualized assessment of stage, sex, genetics, health status, and goals. Charles Medical Group, with Dr. Charles’s 25-plus years of exclusive specialization, more than 15,000 procedures performed, and authorship of the field’s leading textbooks, offers the expertise patients need for informed decision-making.

Take the Next Step: Schedule Your Personalized AGA Consultation

Readers seeking expert evaluation are invited to schedule a complimentary consultation with Dr. Glenn Charles at Charles Medical Group, available in person at Boca Raton or Miami, or virtually via FaceTime and Skype. Consultations are educational and individualized, with no obligation or pressure.

Contact Charles Medical Group at 866-395-5544 or visit charlesmedicalgroup.com. The practice offers transparent pricing with no hidden costs and direct access to Dr. Charles throughout the process. Patients travel from across Florida (Palm Beach, Miami, Fort Lauderdale, Orlando) and from across the United States and internationally to receive care from this distinguished practice.